BioSpace News Archive

Business

Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO)

The program, facilitated by Johnson & Johnson Innovation, has the potential to improve the treatment of patients with retinal vascular diseases and transform the lives of those suffering from vision loss.

January 13, 2020
·
4 min read
Biotech Beach

HealthLytix Joins Nuance AI Marketplace for Diagnostic Imaging

Summary: HealthLytix’s CT CoPilot software for head CT exams to be available to users of Nuance PowerScribe™, the radiology reporting system trusted by approximately 80 percent of U.S. radiologists across more than 7,000 connected healthcare facilities.

January 13, 2020
·
3 min read
ERS Genomics Licenses CRISPR Gene Editing Technology to Daiichi Sankyo to Support Internal Research and Development

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced the signing of a license agreement with Daiichi Sankyo, a global pharmaceutical company with corporate origins in Japan.

January 13, 2020
·
1 min read
Biotech Bay

200G HDR InfiniBand to Accelerate the New European Centre for Medium-Range Weather Forecasts (ECMWF) Supercomputer

The HDR InfiniBand Connected Supercomputer Will Increase the Center’s Weather and Climate Research Compute Power by Five Times, Enabling Enhanced and Far More Accurate Forecast and Predictions

January 13, 2020
·
4 min read
Genetown

bluebird bio Announces Launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype

First agreements with statutory health insurances utilize bluebird’s innovative value-based payment model and provide coverage for ZYNTEGLO for up to 50% of patients in Germany

January 13, 2020
·
8 min read
Deals

Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences

Collaboration Brings Together Gilead’s Commitment to Advancing Cell Therapy with Kyverna’s Focus on Advanced T Cell Engineering Targeting Autoimmune Diseases

January 13, 2020
·
6 min read
Business

Itamar™ Medical Announces Preliminary Revenue for Fourth Quarter and Full Year 2019 and Revenue Guidance for Full Year 2020

Itamar Medical Ltd. reported preliminary unaudited revenue results for the fourth quarter and full year ended December 31, 2019 and announced revenue guidance for the full year 2020.

January 13, 2020
·
5 min read
Business

Emergent BioSolutions Announces Preliminary 2019 Financial Results and Provides 2020 Financial Forecast

Emergent BioSolutions Inc. announced selected preliminary unaudited 2019 financial results and its financial forecast for 2020.

January 13, 2020
·
13 min read
Biotech Beach

Novus Therapeutics Provides Update on OP0201

Phase 2a study C-006 enrollment to be completed in 1Q 2020; data expected in 2Q 2020

January 13, 2020
·
5 min read
Drug Development

Zynerba Pharmaceuticals Announces Achievement of Enrollment Target in Phase 2 Trial of Zygel™ in Autism Spectrum Disorder

Zynerba Pharmaceuticals, Inc., announced the achievement of its enrollment target for the 14-week Phase 2 BRIGHT trial of Zygel™ for the treatment of pediatric and adolescent patients with autism spectrum disorder.

January 13, 2020
·
7 min read